ArticlePharmacotherapy of Borderline Personality DisorderWebber, Michael A. MD; Farrell, Joan M. PhDEditor(s): Janicak, Philip G. MD, Editor Author Information Dr. Webber is Assistant Professor of Clinical Psychiatry, and Dr. Farrell is Assistant Professor of Clinical Psychology, Department of Psychiatry, Indiana University School of Medicine, Adult Outpatient Psychiatry Services, 550 N. University Blvd., Room UH 3124, Indianapolis, IN 46202, E-mail: [email protected]. Dr. Webber has disclosed that he was a stock shareholder of Eli Lilly. Dr. Farrell has disclosed that she has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. The authors also have disclosed that the use of all medications for primary treatment of borderline personality disorder as discussed in this article has not been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Psychopharm Review: November 2008 - Volume 43 - Issue 11 - p 83-89 doi: 10.1097/01.IDT.0000338579.72194.97 Buy CME Test Metrics © 2008 Lippincott Williams & Wilkins, Inc.